Oligonucleotide delivery: Uptake of rat transferrin receptor antibody (OX-26) conjugates into an in vitro immortalised cell line model of the blood-brain barrier

International Journal of Pharmaceutics

Volumn 163, Issue 1-2, 1998, Pages 63-71

  Normand Sdiqui, Nadia ^a   Akhtar, Saghir ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Antisense; Blood brain barrier; Cell uptake; Delivery; Oligonucleotide; Transferrin receptor

Indexed keywords

DRUG CARRIER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX26; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CANCER; CELLULAR DISTRIBUTION; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; ENDOCYTOSIS; EXOCYTOSIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032542782     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00363-3     Document Type: Article

References (20)

1. Abbott, N.J., Couraud, P.O., Roux, F., Begley, D.J., 1995. Studies on an immortalized brain endothelial cell line: characterization, permeability and transport. In: Greenwood, J., Begley, D.J., Segal, M.B., Lightman, S. (Eds.), New Concepts of a Blood-Brain Barrier. Plenum Press, New York, pp. 239-249.
2. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 18:1997;12-18.
3. Bickel U., Yoshikawa T., Landaw E.M., Faull K.F., Pardridge W.M. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc. Natl. Acad. Sci. USA. 7:1993;2618-2622.
4. Boado R.J. Antisense drug delivery through the blood-brain barrier. Adv. Drug Deliv. Rev. 15:1995;73-107.
5. Boado R.J., Pardridge W.M. Complete inactivation of target mRNA by biotinylated antisense oligodeoxynucleotide-avidin conjugates. Bioconj. Chem. 5:1994;406-410.
6. Durieu-Trautman O., Bourdoulous S., Roux F., Bourre J.M., Strosberg A.D., Couraud P.O. Immortalized rat brain microvessel endothelial cells: II. Pharmacological characterization. Adv. Exp. Med. Biol. 331:1993;205-210.
7. Friden P.M., Walus L.R., Musso G.F., Taylor M.A., Malfroy B., Starzyk R.M. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 88:1991;4771-4775.
8. Goldstein G.W., Betz A.L. The blood-brain barrier. Sci. Am. 255:1986;74-83.
9. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gater K.C., Mason D.Y. Transferrin receptor on endothelium of brain capillaries. Nature. 312:1984;162-163.
10. Kuijpers W.H.A., Bos E.S., Kaspersen F.M., Veeneman G.H., Van Boeckel C.A.A. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: A novel approach for two-step radioimmunotherapy of cancer. Bioconj. Chem. 4:1993;94-102.
11. Pardridge W.M. Receptor-mediated peptide transport through the blood-brain barrier. Endocr. Rev. 7:1986;314-330.
12. Pardridge W.M., Boado R.J., Kang Y.-S. Vector-mediated delivery of a polyamide ('peptide') nucleic acid analogue through the blood-brain barrier. Proc. Natl. Acad. Sci. USA. 92:1995;5592-5596.
13. 14C]sucrose through an in vitro blood-brain barrier model, the RBE4 cell line. J. Physiol. 480:1994;8P.
14. Roux, F., Durieu-Trautman, O., Bourre, J.M., Strosberg, A.D., Couraud, P.O., 1993. Immortalized rat brain microvascular endothelial cells: 1 - Expression of blood-brain barrier markers during angionesis. In: Drewes, L.R., Betz, A.L. (Eds.), Frontiers in Cerebral Vascular Biology: Transport and its Regulation. Plenum Press, New York, pp. 201-204.
15. Suzuki S., Pilowsky P., Minson J., Arnolda L., Llewellyn-Smith I.J., Chalmers J. c-fos antisense in rostral ventral medulla reduces arterial blood pressure. Am. J. Physiol. 266:1994;R1418-R1422.
16. Szymkowski D.E. Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Discovery Today. 1:1996;415-428.
17. Tartakoff A. Perturbation of vesicular traffic with the carboxylic ionophore monensin. Cell. 32:1983;1026-1028.
18. Wahlestedt C. Antisense oligonucleotides strategies in neuropharmacology. Trends Pharmacol. Sci. 15:1994;42-46.
19. Walker I., Irwin W.J., Akhtar S. Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm. Res. 12:1995;1-6.
20. Zendegui G., Vasquez K.M., Tinsley J.H., Kessler D.J., Hogan M.E. In vivo stability and kinetics of absorption and disposition of 3′ phosphopropyl amine oligonucleotide. Nucleic Acids Res. 20:1992;307-314.